Discovery of Novel Inhibitors Tailored Around Patient Populations

Proprietary Projects on Small Molecule Targeted Anti-Cancer Therapeutics

NTRC discovers targeted therapies for cancer. Our pipeline consists of selective inhibitors with a long target residence time, with the advantage that pharmacodynamic effects will last even after the drug has been eliminated from systemic circulation. Using advanced bioinformatics we aim to find patient stratification biomarkers for our small molecule inhibitors.

Program

Indications

Preclinical

IND enabling

Phase
1

Phase
2

Phase
3

Upcoming milestones

Partnered

TTK
β-catenin mutant tumors
read more First in human studies ongoing Yes
Progress TTK
BTK
BTK mutant B-cell lymphoma
read more Available
Progress BTK
LCK
Cholangiocarcinoma
read more Available
Progress LCK
TTK Kinase

TTK kinase

  • β-catenin (CTNNB1) mutant tumors

  • Inhibitor series with long target residence time

  • Tumor regression in in vivo studies

  • Status: IND enabling studies

  • Partnered (undisclosed)

BTK Kinase

BTK kinase

  • BTK mutant B-cell lymphoma

  • Selective inhibitor series with high potency

  • Excellent affinity for various BTK mutants

  • Long target residence time

  • Binding to non-activated mutant BTK

LCK Kinase

LCK kinase

  • De-activates Hippo pathway in cholangiocarcinoma

  • Highly selective lead compound

  • Long target residence time

  • Tumor regression in in vivo studies

Back to home